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Abstract 
MicroRNAs are small double-stranded RNAs, which negatively regulate gene 
expression and have been shown to have key roles in both chondrocyte 
development and cartilage homeostasis with age.   
 
Deletion of all microRNAs in chondrocytes leads to skeletal growth defects in 
mice, whilst deletion of specific microRNAs, e.g. miR-140, leads to premature 
articular cartilage degradation and increased susceptibility to post-traumatic 
osteoarthritis.   
 
Studies comparing microRNA expression in normal human articular cartilage 
compared to osteoarthritic cartilage show differential expression, but varying 
sample groups make interpretation difficult.  MicroRNAs have been proposed 
as circulating biomarkers of osteoarthritis, but again, this differs amongst 
patient cohorts.  Many microRNAs have been shown to have roles in 
chondrocyte phenotype via signaling pathways, apoptosis, autophagy and 
senescence.   
 
Modulating microRNAs in the joint has been shown to reduce osteoarthritis in 
animal models and translating this to man as a novel therapeutic strategy will 
be key. 
 
 
Introduction: 
Osteoarthritis (OA) is a degenerative joint disease characterised by 
degradation of articular cartilage, thickening of the subchondral bone, synovial 
inflammation and formation of osteophytes at the joint margin. It is a leading 
cause of disability. The aetiology of OA is complex with genetic, 
developmental, biochemical and biomechanical factors contributing to the 
disease process. The pattern of gene expression and the transcription factors 
that control the development of cartilage (chondrogenesis) are known in 
detail, though mechanisms leading to altered gene expression in OA are less 
well understood. 
 
There is a large body of research that demonstrates that microRNAs, negative 
regulators of gene expression, are crucial in the development of the skeleton 
and in maintaining the homeostasis of cartilage across age.  Further, 
microRNAs are dysregulated in cartilage during OA and have a functional 
effect on disease progression.  This means that modulating specific 
microRNAs in cartilage, may be a novel therapy in osteoarthritis.  MicroRNAs 
may also act as circulating biomarkers in disease.  In the following sections, 
we briefly review each of these areas.   
 
 
The biology of miRNAs 
The first microRNA, lin-4, was discovered in 1981 in Caenorhabditis elegans 
(1). Ambros and Ruvkun  found that lin-4 downregulated lin-14 (a protein 
coding gene), controlling a specific step in development (1-3). The lin-14 
3’UTR harboured multiple sites of imperfect complementarity to lin-4 and it 
was proposed that lin-4 bound to these sites and blocked the translation of lin-
14.  A second miRNA, let-7 was discovered in C.elegans and since this had 
homologues in higher species, this model moved across species.  The term 
‘microRNA’ was then coined for this class of non-coding gene regulators in 
2001 (4-6).  
 
MicroRNAs are evolutionarily conserved, short (~22nt long), double-stranded 
RNA molecules that negatively regulated gene expression at a post-
transcriptional level by binding to specific sequences within target mRNAs (7).  
 
To date, 1917 miRNAs have been identified in human cells (miRBase v22; 
http://mirbase.org/) and each is predicted to regulate several target genes (8). 
Many known miRNAs are located in introns of protein coding genes; a lower 
percentage of miRNAs originate from exons or non-coding mRNA-like regions 
(9). A significant number of miRNA are found in polycistronic units encoding 
more than one miRNA and these are often functionally related (4, 5).  
 
The majority of miRNAs are transcribed by RNA polymerase II and 
subsequently capped and mainly polyadenylated (10, 11). Transcription 
results in a primary miRNA transcript (pri-miRNA) harboring a hairpin 
structure (12)(Figure 1). Within the nucleus, the RNAse II-type molecule 
Drosha and its cofactor DGCR8 process the pri-miRNAs into 70- to 100-nt-
long pre-miRNA structures (13), which in turn are exported to the cytoplasm 
through the nuclear pores by Exportin-5 (14). Subsequently, the RNAse III-
type protein Dicer generates a double-stranded short RNA in the cytoplasm 
(15). This duplex miRNA is unwound by a helicase into single-stranded short 
RNA in the cytoplasm. One strand of the miRNA duplex is selected as the 
guide miRNA and remains stably associated with the miRNA-induced 
silencing complex (mRISC); the other strand, known as the passenger strand, 
can be rapidly degraded (16). The strand with less-stable base pairing at its 5’ 
end is usually destined to become the active strand (17), however, some 
miRNA ‘passenger’ strands are themselves active and can negatively regulate 
gene expression.  The mature miRNA guides the mRISCs mainly to the 
3’UTR of its target miRNA (18). The seed sequence, comprising nucleotides 
2-8 at the 5’-end of the mature miRNA, is the most important for binding of the 
miRNA to its target site in the mRNA (18), though other sequences such as 
the supplementary region (nucleotides 13-16) are increasingly seen as vital 
for effective target repression (19).  
 
In an alternative pathway for miRNA biogenesis, short hairpin introns termed 
mirtrons are spliced and debranched to generate pre-miRNA hairpin mimics 
(20). These are then cleaved by Dicer in the cytoplasm and incorporated into 
typical miRNA silencing complexes. The presence of mirtrons may be an 
evolutionary strategy to diversify miRNA-based gene silencing (21). 
 
The degree of base pairing between the miRNA and its target in the mRISC 
determines the fate of the transcript. If there is perfect complementarity 
between the miRNA and target, the mRNA target is cleaved by Ago2 at the 
annealing site, with subsequent degradation of the mRNA.  In contrast, where 
the miRNA is only partially complementary to its corresponding 3’UTR (almost 
all cases in mammals), inhibition of target mRNA translation occurs via Ago1 
(22).  
 
 
The skeletal impact of deleting microRNAs 
The mutation or deletion of Dicer, prevents the biogenesis of the majority of 
microRNAs, demonstrating a role for the class in skeletal development.  
Conditional knockout of Dicer in limb mesenchyme at the early stages of 
embryonic development leads to the formation of a smaller limb (23).  Dicer 
null growth plates show lack of chondrocyte proliferation, but also enhanced 
hypertrophy (23).  Conditional knockout of Dicer in chondrocytes results in 
skeletal growth defects and premature death (24) with a similar phenotype in 
conditional Drosha knockouts (25).  The deletion of specific microRNAs is 
discussed below. 
 
 
Differential expression of microRNAs in cartilage 
There have been many reports of microRNAs being differentially expressed in 
cartilage from osteoarthritis patients compared to normal cartilage (e.g. (26-
29)). For microarray or RNA-Seq screens of expression, these do not give 
consistent differentially expressed microRNAs, likely due to sample 
differences.  However, the identity of specific microRNAs has been the 
starting point for several studies. 
 
An analysis of the published literature on the expression of microRNAs and 
OA was performed by Cong et al.  This identified 46 differentially expressed 
microRNAs involved in a number of processes including apoptosis and 
autophagy, differentiation, metabolism, ECM degradation and inflammation in 
chondrocytes (30). 
 
The ‘functional’ microRNAs within chondrocytes have been assessed using 
AGO2 immunoprecipitation to identify microRNAs in the RISC complex.  In 
cells taken from the cartilage of either OA patients or normal controls,  miR-
27b-3p was most abundant, with miR-140-3p (see below) eighth most 
abundant (31). 
 
A powerful technique was utilized by Coutinho de Almeida et al. who 
performed both mRNA-Seq and miRNA-Seq from OA lesion and 
macroscopically normal cartilage from the same patient (32).  This enabled 
the construction of a so-called interactome of differentially expressed mRNAs 
and miRNAs.  Amongst much data, miR-99a-3p was downregulated in OA 
lesions and targets 36 differentially expressed mRNAs, three of them showing 
strong correlation (FZD1, ITGB5, GSF6), whilst miR-143-5p is increased in 
the OA lesions and targets 16 differentially expressed mRNAs including the 
strongly correlated DCAKD, AMIGO1 and SMAD3 genes. 
 
Some information on the role of microRNAs in cartilage development, 
homeostasis and osteoarthritis is given below. 
 
 
MicroRNAs and chondrogenesis 
Many microRNAs have been identified which target transcription factors or 
signaling molecules involved in chondrogenesis and which therefore regulate 
the process.  MicroRNAs may therefore be useful in cartilage repair or 
engineering e.g. (33, 34). 
 
Amongst myriad examples, Sox9 induces expression of many microRNAs, 
with miR-140 particularly responsive (35).  The microRNA-140 null mouse has 
a clear skeletal phenotype, as below, with a decrease in proliferating 
chondrocytes in the growth plate (36, 37).  This is at least in part via its ability 
to target Sp1 and alter cell cycle (38).  A number of other targets for miR-140-
5p have been identified during hMSC chondrogenesis in vitro, including RALA 
and FZD6 (39, 40).   
 
MiR455 is co-regulated with miR-140 in both ATDC5 and hMSC models of 
chondrogenesis (39, 41) and is also highly Sox9 inducible (39).  miR-455-3p 
has also been shown to act in early chondrogenic differentiation via direct 
targeting of Runx2 (42) and potentially HDAC2 and HDAC8 (43).  It may also 
impact on DNA methylation during chondrogenesis via DNMT3A (44). 
 
 
MicroRNA and signaling 
MicroRNAs have been shown to regulate and be regulated by many signaling 
pathways implicated in OA and it is beyond the scope of this review to explore 
them in any detail. 
 
To give one example, TGFβ both regulates the expression of a number of 
microRNAs and TGFβ/Smad signaling is regulated by both the same and 
different microRNAs.  For example, TGFβ reduces the expression of miR-140 
(45) whilst Smad3 was identified as a direct target of miR-140-5p (46).  
Similarly, TGFβ reduces expression of miR-29 in many cell types including 
chondrocytes (47), and this is Smad3 dependent, at least in renal fibrosis 
(48).  However, miR29 can suppress TGFβ signaling (47).  Conversely, TGFβ 
induces expression of miR-455 in chondrocytes, whilst miR-455 suppresses 
TGFβ signaling via directly targeting Smad2  (41).  Hence, both feedforward 
and feedback loops exist between TGFβ signaling and microRNAs. 
 
MicroRNAs have been shown in chondrocytes to regulate Smad2 and 3 
(above) but also Smad4.  MicroRNA-483 was identified as significantly 
decreased in expression in chondrocyte hypertrophy (49).  Overexpression of 
miR-483 showed that it downregulated Smad4 to suppress chondrogenesis 
and reduce extracellular matrix production.  Interestingly, levels of Smad4 
mRNA were not altered by miR-483 overexpression, but protein levels were 
and this is the same for miR-140-5p and Smad3 above (46). 
 
MicroRNAs have been shown to impact on the majority, if not all, of the 
signaling pathways pertinent to OA, though the role this has in pathogenesis 
is unclear. 
 
 
MicroRNAs and chondrocyte apoptosis / senescence / autophagy 
A number of different microRNAs were initially shown to inhibit apoptosis, but 
sometimes also to enhance apoptosis via a number of targets and 
mechanisms.  This research has broadened to implicate microRNAs in the 
regulation of autophagy and senescence too, all potentially key components 
of OA pathogenesis.  Some examples are given below. 
 
MicroRNA-34a was the first microRNA to be linked to chondrocyte apoptosis, 
with an inhibitor of miR-34a reducing IL-1-induced apoptosis in rat 
chondrocytes (50).  MicroRNA-34a is increased in expression in human OA 
cartilage compared to control, whilst SIRT1, shown to be a direct target, was 
decreased (51).  This led to less acetylation of p53, increase in the pro-
apoptotic Bax and decrease in the anti-apoptotic Bcl-2 and an increase in 
chondrocyte apoptosis.  Markers of autophagy were also decreased in 
chondrocytes by miR-34a over expression (52).  Zhang et al 2018 reported 
that a miR-34a mimic increased both cell death and senescence in 
chondrocytes via targeting the Notch pathway (53).  Both Zhang et al and Yan 
et al showed that intraarticular injection of a miR-34a inhibitor in a model of 
OA abrogates cartilage destruction (51, 53). 
 
MicroRNA-24 regulates the cell cycle inhibitor P16INK4a, a marker of 
senescence.  P16INK4a and other markers of the senescence-associated 
secretory phenotype (SASP) increase in OA and in terminal chondrogenesis , 
whilst miR-24 is decreased (54). 
 
MicroRNA-495 is also elevated in human OA cartilage (55).  MicroRNA-495 
overexpression increases chondrocyte apoptosis and also increases markers 
of senescence (SA-β-gal and p16), via direct targeting of AKT1 and the S6-
mTOR system.  Intra-articular injection of a miR-495 inhibitor in a rat model of 
OA induced by anterior cruciate ligament transection (ACLT) decreased OA 
and decreased chondrocyte apoptosis.  Yang et al 2019 also show that 
inhibition of miR-495 suppresses apoptosis through activation of the NFκB 
pathway and CCL4, the latter a potential direct target for miR495 (56). 
 
When cells are under stress, autophagy can be activated to prevent apoptosis 
and a number of microRNAs have been reported to do this. Recent examples 
include: expression of miR-335-5p was lower in OA than normal 
chondrocytes, with overexpression increasing autophagy whilst reducing 
inflammation (57);  Zhao et al 2019 showed that expression of miR-107 was 
lower in OA chondrocytes than control and again, overexpression inhibited 
apoptosis and increased autophagy (58). 
 
Interestingly, extracellular vesicles (EVs) from senescent cells taken from 
chondrocytes from human OA cartilage can transfer senescence to non-
senescent chondrocytes and inhibit cartilage formation by these cells (59).  
These EVs contained less miR-140-3p and more miR-34a that EV derived 
from non-senescent chondrocytes.  Clearance of senescent cells (SnC) 
resulted in decreased miR-34a in synovial fluid derived EVs from young 
mouse joints with post traumatic OA (ACLT), though no differences were seen 
in older animals.  A complete analysis of microRNAs in synovial EVs from 
mice with PTOA showed that a number of microRNAs alter, though only miR-
223 decreases in both young and old mice with PTOA after senolytic 
treatment (59). 
 
 
Deletion of specific microRNAs 
Whilst the initial studies showed that microRNAs, as a class, are functionally 
important in skeletogenesis (see above), the role of individual microRNAs in 
development or in osteoarthritis in vivo, is less well explored. 
 
By far the most studied microRNA in cartilage is microRNA-140.  Originally 
described as expressed in a skeletally restricted pattern in the developing 
zebrafish (60), this was then confirmed in the mouse (61).  MicroRNA-140-5p 
has been shown to directly mediate expression of e.g. IGFBP-5, MMP13, 
Hdac4, Cxcl12, Bmp2 and Smad3 (45, 46, 62), all of which are implicated in 
chondrocyte development and/or cartilage homeostasis.  However, it appears 
that miR-140-3p is the most abundantly expressed in cartilage and it may be 
that miR-140-5p is most important in development (39, 40), whilst miR-140-3p 
potentially has a greater role in tissue homeostasis. 
 
The expression of miR-140 in knee cartilage from osteoarthritis patients was 
decreased compared to normal cartilage (though these were not age-matched 
groups) (63).  The complete knockout of miR-140 in mice leads to mild 
dwarfism, with impaired chondrocyte differentiation / proliferation (36, 37).  
Deletion of miR-140 also predisposed mice to the development of 
spontaneous age-related cartilage breakdown (36, 37) and increased 
cartilage destruction in surgically-induced OA (36). Key targets identified 
include ADAMTS5 (36) and the aspartyl aminopeptidase Dnpep (37), but 
many more targets exist which likely contribute to the phenotype.  The 
deletion of miR-140 also interacts with inhibition of let-7 microRNAs in the 
mouse to give a more severe skeletal phenotype than either single mutation 
(64). 
 
The relevance of miR-140 to human disease was recently proven when a rare 
autosomal dominant skeletal dysplasia, found in two families, was tracked to a 
mutation in the seed sequence for miR-140-5p (65).  This single base 
substitution was reiterated in knock-in mice, demonstrating a neomorphic 
phenotype and not simply loss of function.   
 
Another well-researched microRNA is miR-146a, whose expression is 
stimulated by many inflammatory mediators and with roles in the immune 
system and inflammation (66).  MicroRNA-146a is highly expressed in 
cartilage from early stage human osteoarthritis patients (67) and may 
modulate pain in disease (68).  It is reported to have effects on inflammation, 
chondrocyte autophagy and apoptosis and the expression of extracellular 
matrix genes (e.g. (69-72))  
 
Recently, a miR-146a null mouse showed decreased cartilage destruction 
both spontaneously and in three different models of induced osteoarthritis 
(destabilization of the medial meniscus DMM, partial medial meniscectomy 
PMM and anterior cruciate ligament transection ACLT) (73) . Intraarticular 
delivery of a miR-146a inhibitor decreased cartilage destruction in surgically 
induced OA, with target genes, calcium/calmodulin-dependent protein kinase 
II delta (Camk2d) and protein phosphatase 4, regulatory subunit B, beta 
isoform (Ppp3r2) identified as essential in regulating cartilage homeostasis.  
In contrast to this, Guan et al (74) showed that miR-146a expression is 
decreased in lesions compared to non-lesions in human OA cartilage.  They 
went on to characterize miR-146a null mice as developing early onset 
spontaneous OA, whilst conversely, a mouse overexpressing miR-146a in a 
chondrocyte-specific manner was protected from such disease.  Furthermore, 
miR-146a null mice were more susceptible to instability induced OA and the 
conditional overexpressing mice were again protected.  This appears to be via 
the ability of miR-146a to target Notch1, with intraarticular delivery of a Notch1 
inhibitors rescuing joint destruction in the miR-146a null mice.  Clearly these 
conflicting data require resolution.  
 
MicroRNA-21-5p was increased in expression in human cartilage from 
osteoarthritis patients compared to normal controls.  Cartilage specific 
deletion of miR-21 in mice decreased spontaneous cartilage lesions and 
protected from induced osteoarthritis (75). 
 
Finally, miR-128a is increased in expression in human cartilage from 
osteoarthritis patients compared to normal controls and targets Atg12 to 
repress chondrocyte autophagy (76).  A recent meeting report suggests that a 
cartilage-specific miR-128a null mouse had decreased osteoarthritis in both 
DMM and collagenase-induced OA models (77) 
 
As described above for miR-140 and miR-146a above, the overexpression of 
a microRNA in vivo may also allow the dissection of its function.  In order to 
explore data suggesting that intraarticular delivery of miR-483-5p increased 
severity and progression of OA in the DMM model, Wang et al used an 
inducible transgenic mouse overexpressing miR-483.  This mouse again 
showed an increase in spontaneous and induced OA via targeting of matrilin 3 
and Timp2 (78). 
 
 
MicroRNAs as biomarkers of OA 
Since microRNAs are found in the circulation and exhibit good stability there, 
the possibility that their plasma levels act as a biomarker of disease status is 
clearly attractive.   
 
Beyer et al 2014 used a Taqman microarray screen to measure the levels of 
374 microRNAs in the pooled plasma of a sub-group of patients in a 
longitudinal cohort who had or hadn’t progressed to joint replacement.  
Identified microRNAs were then assayed in the entire cohort to show that let-
7e, miR-454 and miR-885-5p were potentially predictive of OA progression.  
Let-7e was decreased in the plasma of osteoarthritis patients compared to 
control with robust statistical analyses (79).   
 
A similar screen Taqman microarray screen was performed by Borgonia 
Cuadra et al 2014 which identified 12 microRNAs with statistically different 
levels in OA plasma compared to controls in two cohorts (80).  
 
Kong et al 2017 used a microarray to measure 2578 mature microRNAs in OA 
compared to normal plasma identifying 70 differentially expressed 
microRNAs.  Eight of these were validated by qPCR to identify miR-19b-3p, 
miR-122-5p and miR-486-5p as independent factors for the risk of knee OA, 
with miR-19b-3p and miR-486-5p positively correlating with disease severity 
(81).   
 
Ntoumou et al 2017 also used a further microarray to measure 2549 
microRNAs in OA vs. control plasma, identifying 279 differentially expressed 
microRNAs. QPCR validation identified miR-140-3p, miR-33b-3p and miR671-
3p as potential biomarkers (82).  
 
Across these studies, there were no validated microRNAs which were 
identified in all four as significant.  A number of microRNAs (miR-122, miR-
885, miR-140, miR-93 and miR-663a) were identified in two of the studies.  
This likely reflects differences in patient groups and numbers but also 
differences in the extent and methodology of measurement. 
 
Several other studies have measured specific microRNAs as potential 
circulating biomarkers of osteoarthritis too (83-86). 
 
 
The therapeutic use of microRNAs in OA 
In order to be used therapeutically, microRNA mimics or their inhibitors must 
be successfully introduced to the joint and taken up into joint tissues e.g. 
cartilage.  As proof-of-concept of this, the majority of studies have used 
intraarticular injection of microRNA- or inhibitor-expressing lentivirus in mouse 
and rat models of OA.  Examination of cartilage integrity shows efficacy, but 
doesn’t demonstrate uptake into cartilage itself, though measurement of 
known microRNA targets in cartilage tissue act as a surrogate for this.  
However, Lian et al 2018 used lentivirus to deliver miR-128a or its inhibitor to 
the joint.  They then demonstrated uptake into cartilage and chondrocytes 
using in situ hybridisation (ISH) as well as functional outcome where 
microRNA-128a mimic increased OA score and miR-128a inhibitor decreased 
OA score (76).  Similarly, Wang et al 2017 delivered miR-483 intraarticularly 
using lentivirus and showed uptake into cartilage using ISH and also via co-
expressed GFP expression in mid and deep zone chondrocytes. Dai et al 
2015 use an adenoviral delivery of miR101 or an inhibitor to the joint in a rat 
MIA model and again use a GFP tag to demonstrate full depth penetration of 
the virus and expression (87). 
 
Viral delivery to the mouse knee is simply proof-of-concept and is associated 
with several risks that make it unlikely to be translated to man.  Non-viral 
delivery systems are also being developed.  Interestingly, Wang et al. also 
delivered an inhibitor of miR-483 directly to the joint (i.e. not virally) and show 
functional outcome (78).  This was also achieved by Nakamura et al, who 
inject a short (16 mer) antisense LNA oligonucleotide intraarticularly in the 
DMM model of OA and show both histological improvement of OA and a 
concurrent decrease in OA markers (88). 
 
MicroRNAs can be packaged into exosomes, nanometre scale particles 
produced by the majority of cells.  Indeed, microRNAs can circulate through 
the bloodstream in this way and exosomes can be taken up by distant cells 
(89).  This strongly suggests that exosomes could be used for therapeutic 
delivery of microRNAs.  Mao et al have used exosomes produced by human 
mesenchymal stem cells which were transfected with miR-92a-3p or an 
inhibitor and introduced these by intraarticular injection into a collagenase-
induced OA model in the mouse.  They used in situ hybridisation to show 
expression of miR-92a-3p by cartilage chondrocytes and demonstrated a 
functional effect (90) .  Similarly, Tao et al use exosomes from miR-140-5p 
transfected synovial MSC injected intraarticularly in a rat ACLT model to show 
decreased OA (91) 
 
All of these studies are in rodent models and trials of microRNA delivery to the 
joint in man have yet to be conducted. 
 
Crossing over with the use of microRNAs as biomarkers in OA, Kohle et al 
measured exosomal microRNAs in the synovial fluid of patients with OA 
compared to normal controls.  This study demonstrated differential levels of 
several microRNAs in OA, with gender-specific differences in the pattern of 
microRNAs identified.  This may both help understand pathogenesis of 
disease and microRNAs which may be therapeutic in OA (92). 
  
 
Conclusion: 
As in many fields of biology, a huge number of microRNAs have been 
implicated in cartilage physiology and pathology.  Detailed studies on the 
function of single microRNAs in vitro and ultimately in vivo in knockout or 
transgenic mice will delineate the roles of specific microRNAs and 
intraarticular delivery of these microRNAs or their inhibitors may be 
therapeutic in OA.  However, given that a single microRNA can target many 
mRNAs and that each mRNA can be the target for several microRNAs, it is 
clear that really understanding the system will require a mathematical 
modeling approach.  Combining data from the research described above and 
further research, at all scales, will enable us to build better networks of 
microRNA (and mRNA) function in osteoarthritis, identifying key microRNAs 
as ideal targets for therapeutic intervention.  Whilst this review has focused on 
cartilage, a similar story exists in other relevant tissues of the joint and again, 
understanding the interplay between these tissues at the level of microRNAs 
will be crucial. 
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Figure 1:  Biogenesis of microRNAs.   MicroRNAs are transcribed as 
primary transcripts (pri-miRNAs) and processed by Drosha/DGCR8 to hairpin 
precursors (pre-miRNAs).  These are exported to the cytoplasm and further 
processed by Dicer into the mature double-stranded miRNA.  The duplex is 
unwound and one strand (guide) incorporated into RISC whilst the other 
strand (passenger) is degraded.  The miRNA-RISC complex acts either to 
degrade its mRNA target where homology is high, or to inhibit translation, 
leading to mRNA degradation, where homology is lower. 
  
Figure 2:  Examples of the roles of microRNAs in osteoarthritis.  A 
number of microRNAs have been shown to be dysregulated in osteoarthritic 
cartilage and to have functions in chondrogenesis, chondrocyte autophagy, 
apoptosis, senescence, intracellular signaling and inflammation.  Data from 
human cartilage, cells or plasma is shown on the left hand side with 
complementary data from mouse models on the right hand side. 
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